Immutep Stock Price, News & Analysis

Immutep has announced positive results from the Phase II TACTI-002 trial, evaluating the combination of eftilagimod alpha (efti) and pembrolizumab (KEYTRUDA) in 1^st line non-small cell lung cancer (NSCLC) patients. The study met its primary objective with an Overall Response Rate (ORR) of 38.6% across 114 patients, exceeding historical anti-PD-1 monotherapy results. Notably, responses were observed in patients with low or negative PD-L1 expression. The treatment was reported safe and well-tolerated, supporting further late-stage development.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on June 7, 2022, to discuss new data from its Phase II TACTI-002 trial for non-small cell lung cancer (NSCLC). This data will be presented at the ASCO 2022 Annual Meeting on June 3, 2022. Immutep's CEO Marc Voigt and other executives will speak during the webcast. Their lead product, eftilagimod alpha, is a LAG-3 related immunotherapy treatment for cancer and autoimmune diseases. The company aims to enhance treatment options for patients and value for shareholders.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has released interim data from its Phase II TACTI-002 trial, demonstrating positive antitumor activity of eftilagimod alpha in first-line non-small cell lung cancer (NSCLC) patients. The Overall Response Rate (ORR) improved to 37.3% among the 75 patients, up from 36.1% reported at ASCO 2021, with a Disease Control Rate (DCR) of 73.3%. Efti combined with pembrolizumab remains safe and well-tolerated. Data from all 114 patients will be presented on June 3, 2022, along with updates on the ongoing Phase IIb TACTI-003 trial.

Immutep Limited (NASDAQ: IMMP) announced its participation in several upcoming investor conferences, showcasing its advancements in immunotherapy for cancer and autoimmune diseases. Key events include:

• Wilsons Rapid Insights: 26 May 2022, in-person, with Marc Voigt and Deanne Miller presenting.
• Jefferies Australia MedTech/Biotech Summit: 26-27 May 2022, virtual presentation by Marc Voigt.
• Jefferies Global Healthcare Conference: 8-10 June 2022, in-person, with a live webcast on 10 June.

Immutep is at the forefront of developing LAG-3 related immunotherapy solutions.

Immutep announced the appointment of four new members to its Clinical Advisory Board (CAB), enhancing its strategic resources for advancing LAG-3-related immunotherapy treatments. The new members, experts in oncology and immunotherapy, will focus on late-stage development programs for the lead product, eftilagimod alpha. This move aims to strengthen Immutep's position as a leader in innovative cancer therapies, especially targeting metastatic breast and non-small cell lung carcinomas.

Immutep reported results from its Phase IIb AIPAC trial, demonstrating a statistically significant increase in immune response biomarkers such as monocyte and CD8 T cell counts in the efti treatment group compared to placebo. These biomarkers are correlated with improved overall survival (OS), as shown in an exploratory analysis identifying six patient subgroups that benefit from the treatment. Notably, five subgroups showed significant OS improvements, with ALC emerging as a potential predictor for survival.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) recently announced new interim data from the Phase II TACTI-002 trial for NSCLC patients showing an encouraging overall survival rate of 73.7% at the six-month mark.

Additionally, the company received constructive FDA feedback on the efti development program for metastatic breast cancer (MBC) and is proceeding with recruitment for Phase IIb TACTI-003. Immutep's cash balance is strong at $87.2 million as of March 31, 2022, despite an increase in R&D spending.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced that interim data from the Phase II TACTI-002 trial for non-small cell lung cancer will be presented at the ASCO 2022 Annual Meeting, taking place from June 3-7, 2022. The trial evaluates the combination of eftilagimod alpha and pembrolizumab. Additionally, TACTI-003 trial design will be showcased. The presentation includes significant new data not mentioned in the abstract, with over 40,000 attendees expected to participate in this prominent conference.

Immutep Limited (NASDAQ: IMMP) announced encouraging interim results from its Phase II TACTI-002 trial for 2nd line metastatic non-small cell lung carcinoma (NSCLC). Key findings include a Disease Control Rate (DCR) of 36.1% and a 73% overall survival rate at six months. 73.7% of patients experienced tumor shrinkage or deceleration, with 5.6% achieving durable partial responses. The treatment, combining eftilagimod alpha (efti) with pembrolizumab, continues to demonstrate safety and tolerability. More mature data is anticipated later this year.